How to buy Kaleido Biosciences stock - 18 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Kaleido Biosciences stock

Own Kaleido Biosciences stock in just a few minutes.

Kaleido Biosciences, Inc is a biotechnology business based in the US. Kaleido Biosciences shares (KLDO) are listed on the NASDAQ and all prices are listed in US Dollars. Kaleido Biosciences employs 82 staff and has a trailing 12-month revenue of around USD0.00.

How to buy shares in Kaleido Biosciences

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Kaleido Biosciences. Find the stock by name or ticker symbol: KLDO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Kaleido Biosciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Kaleido Biosciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Kaleido Biosciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Kaleido Biosciences share price

Use our graph to track the performance of KLDO stocks over time.

Kaleido Biosciences shares at a glance

Information last updated 2021-04-15.
52-week rangeUSD$5.04 - USD$16.929
50-day moving average USD$8.9374
200-day moving average USD$9.4073
Wall St. target priceUSD$16.57
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-6.237

Buy Kaleido Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Kaleido Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kaleido Biosciences financials

Revenue TTM USD$975,000
Gross profit TTM USD$-54,992,000
Return on assets TTM -69.6%
Return on equity TTM -235.29%
Profit margin 0%
Book value $0.569
Market capitalisation USD$344.6 million

TTM: trailing 12 months

Shorting Kaleido Biosciences shares

There are currently 2.8 million Kaleido Biosciences shares held short by investors – that's known as Kaleido Biosciences's "short interest". This figure is 11.7% up from 2.5 million last month.

There are a few different ways that this level of interest in shorting Kaleido Biosciences shares can be evaluated.

Kaleido Biosciences's "short interest ratio" (SIR)

Kaleido Biosciences's "short interest ratio" (SIR) is the quantity of Kaleido Biosciences shares currently shorted divided by the average quantity of Kaleido Biosciences shares traded daily (recently around 251016.96428571). Kaleido Biosciences's SIR currently stands at 11.2. In other words for every 100,000 Kaleido Biosciences shares traded daily on the market, roughly 11200 shares are currently held short.

However Kaleido Biosciences's short interest can also be evaluated against the total number of Kaleido Biosciences shares, or, against the total number of tradable Kaleido Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kaleido Biosciences's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Kaleido Biosciences shares in existence, roughly 70 shares are currently held short) or 0.1346% of the tradable shares (for every 100,000 tradable Kaleido Biosciences shares, roughly 135 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Kaleido Biosciences.

Find out more about how you can short Kaleido Biosciences stock.

Kaleido Biosciences share dividends

We're not expecting Kaleido Biosciences to pay a dividend over the next 12 months.

Kaleido Biosciences share price volatility

Over the last 12 months, Kaleido Biosciences's shares have ranged in value from as little as $5.04 up to $16.929. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kaleido Biosciences's is -0.3145. This would suggest that Kaleido Biosciences's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Kaleido Biosciences has bucked the trend.

Kaleido Biosciences overview

Kaleido Biosciences, Inc. , a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of immuno-oncology, and cardiometabolic and liver diseases. The company has collaboration agreements with Gustave Roussy Cancer Center, Washington University School of Medicine, and Janssen. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site